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Background. While thinner struts are associated with improved clinical outcomes in bare-metal stents (BMS), reducing strut
thickness may affect drug delivery from drug-eluting stents (DES) and there are limited data comparing otherwise similar thin and
thick strut DES. We assessed 2-year outcomes of patients treated with a thin strut (84–88um) cobalt-chromium, biodegradable
polymer, Biolimus A9-eluting stent (CoCr-BP-BES) and compared these to patients treated with a stainless steel, biodegradable
polymer, Biolimus A9-eluting stent (SS-BP-BES). Methods. In total, 1257 patients were studied: 400 patients from 12 centres
receiving ≥1 CoCr-BP-BES in the prospective Biomatrix Alpha registry underwent prespecified comparison with 857 patients who
received ≥1 Biomatrix Flex SS-BP-BES in the LEADERS study (historical control). .e primary outcome was major adverse
cardiac events (MACE)—cardiac death, myocardial infarction (MI), or clinically driven target vessel revascularization (cd-TVR).
Propensity analysis was used to adjust for differences in baseline variables and a landmark analysis at day-3 to account for
differences in periprocedural MI definitions. Results. MACE at 2 years occurred in 6.65% CoCr-BP-BES versus 13.23% SS-BP-BES
groups (unadjusted HR 0.48 [0.31–0.73]; P � 0.0005). Following propensity analysis, 2-year adjusted MACE rates were 7.4%
versus 13.3% (HR 0.53 [0.35–0.79]; P � 0.004). Definite or probable stent thrombosis, adjudicated using identical criteria in both
studies, occurred less frequently with CoCr-BP-BES (1.12% vs. 3.22%; adjusted HR 0.32 [0.11–0.9]; P � 0.034). In day-3 landmark
analysis, the difference in 2-year MACE was no longer significant but there was a lower patient-orientated composite endpoint
(11.7% vs. 18.4%; HR 0.6 [0.43–0.83]; P � 0.006) and a trend to lower target vessel failure (5.8% vs. 9.1%; HR 0.63 [0.4–1.00];
P � 0.078). Conclusion. At 2-year follow-up, propensity-adjusted analysis showed the thin strut (84–88um) Biomatrix Alpha
CoCr-BP-BES was associated with improved clinical outcomes compared with the thicker strut (114–120um) Biomatrix Flex SS-
BP-BES.
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1. Introduction
.inner stent struts may improve deliverability and con-
formability and reduce vessel injury. A comparison of bare-
metal stents with identical design apart from strut thickness
reported improved clinical outcomes with thinner struts,
specifically a lower incidence of angiographic restenosis and
repeat revascularization [1]. However, reducing strut
thickness may affect drug delivery from drug-eluting stents
(DES). Furthermore, most trials evaluating DES with
thinner versus thicker struts have compared stents with
different designs and/or different polymers and/or different
drugs [2]. We thus aimed to assess the clinical impact of
reducing strut thickness in DES by comparing two otherwise
similar DES, apart from a difference in strut thickness. We
also assessed clinical outcomes to 2 years to mitigate the
potentially confounding effect of different durations of dual
antiplatelet therapy (DAPT) in earlier follow-up.
2. Materials and Methods
2.1. StentDesign. In this paper, we describe 2-year outcomes
after a percutaneous coronary intervention (PCI) with the
Biomatrix AlphaTM cobalt-chromium, biodegradable poly-
mer, Biolimus A9 eluting stent (CoCr-BP-BES) and the
Biomatrix FlexTM stainless steel, biodegradable polymer,
Biolimus A9 eluting stent (SS-BP-BES). Both stents are
abluminally coated with a mixture of Biolimus A9 and a
polylactic acid (PLA) polymer matrix (50 : 50 by weight) in a
dose of 15.6 µg/mm stent length. Biolimus A9 is an m-TOR
inhibitor with a cytostatic mechanism of action similar to
sirolimus but custom-designed with a ligand modification
which results in 10-fold increased lipophilicity. PLA is
biodegradable and fully absorbed within 6–9 months. While
drug and polymer are identical in formulation and dose, the
Biomatrix AlphaTM CoCr-BP-BES platform is made from
cobalt-chromium (MP35N) which has enabled a reduction
in strut thickness from 114–120 µm (in the 316L stainless
steel Biomatrix FlexTM SS-BP-BES) to 84–88 µm while
maintaining similar radial strength. All other stent design
elements have remained unchanged including the hybrid
design of mid-section S-connectors for improved flexibility
combined with straight connectors for higher longitudinal
strength in the proximal and distal end sections of the stent
[3].
2.2. Study Design and Patients. .e Biomatrix Alpha™
Registry [3] was a prospective, single-arm, multicentre
registry conducted in 12 centres across 4 countries in Europe
and Asia, which enrolled 400 patients with stable coronary
artery disease or acute coronary syndrome receiving at least
one Biomatrix AlphaTM CoCr-BP-BES. Patients were eli-
gible for inclusion if they had undergone PCI in one or more
coronary arteries or bypass grafts. .ere were no limitations
as to the number of treated vessels, or the number, type, and
length of treated lesions. Patients were excluded if any
additional stent(s) different from the study stent were
implanted during the index procedure. .e registry was
managed by the Cardiovascular European Research Center
(CERC) in Massy, France. .e primary endpoint was the
incidence of major adverse cardiac events (MACE) at 9
months—a composite of cardiac death, myocardial infarc-
tion (MI), and clinically driven target vessel revasculariza-
tion (cd-TVR). We previously reported the incidence of
MACE at 9 months to be 3.94% (95% CI [2.39–6.47]) which
met criteria for noninferiority (P< 0.001) versus the SS-BP-
BES arm of the LEADERS study [4]. In this paper, we report
clinical outcomes up to 2 years. Secondary endpoints in-
cluded target vessel failure (TVF), a composite of cardiac
death or target vessel (TV), MI, or cd-TVR; the patient-
oriented composite endpoint (POCE), a composite of all-
cause mortality, any MI, or any revascularization; individual
components of the composite endpoints; and ARC definite
or probable stent thrombosis.
.e LEADERS study [4] was a randomized compar-
ison of 857 patients receiving at least one SS-BP-BES
(Biomatrix FlexTM) versus 850 patients receiving a
stainless steel, permanent polymer, and sirolimus-eluting
stent (SS-PP-SES) (Cypher™, Cordis, Miami Lakes, FL,
USA). .e SS-BP-BES group showed noninferiority with
respect to MACE at 9 months (which was maintained at 5
years) and a significant reduction in very late definite ST
from 1 to 5 years compared with the SS-PP-SES group [5].
Key elements of the Biomatrix Alpha registry protocol
were intentionally kept the same as in the LEADERS
study, to enable a prespecified comparison of patients
receiving CoCr-BP-BES stents versus patients in the SS-
BP-BES arm of the LEADERS study [4] as a historic
control. DAPT with aspirin and a P2Y12 inhibitor was
recommended as per clinical practice guidelines in the
Biomatrix Alpha registry and for at least one year in the
LEADERS study.
2.3. Data and definitions. Both studies were conducted in
accordance with good clinical practice (GCP) guidelines and
the 1975 Declaration of Helsinki. Both were registered with
Clinicaltrials.gov and informed consent from each patient
was obtained. Baseline data have been described previously
[3, 4]. All reported MACE and stent thrombosis events in
both studies were monitored, checked against source doc-
uments, and adjudicated by an independent Clinical Event
Committee (CEC). Cardiac death was defined as any death
due to immediate cardiac cause (e.g., MI, low-output failure,
fatal arrhythmia), unwitnessed death, or death of unknown
cause. In the Biomatrix Alpha registry, MI was defined by the
.ird Universal Definition ofMI [6]. In the LEADERS study,
MI was defined by Minnesota code ECG criteria or creatine
kinase (CK) >2x upper limit of normal with elevated CK-MB
or troponin. cd-TVR was defined as a repeat PCI or bypass
surgery of the target vessel associated with either a≥ 70%
vessel diameter reduction or a≥ 50% diameter reduction in
combination with angina and/or documented ischemia.
Stent thrombosis was categorized as definite or probable
according to the Academic Research Consortium (ARC)
definitions [7, 8] with all relevant angiograms reviewed by
the CEC.
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2.4. Statistical Analysis. For continuous variables, mean and
standard deviation are reported. For categorical variables,
counts and percentages are shown. .e denominator for the
calculation of percentages is based upon the number of the
nonmissing values available unless otherwise specified.
Clinical events are reported as Kaplan–Meier estimates with
corresponding confidence intervals based on the log-log
transformation and hazard ratio (HR) derived from the Cox
proportional hazard model. All data were analysed using
SAS V.9.4 (SAS Institute, Cary, North Carolina, USA).
In order to adjust for potential baseline differences, we
conducted a patient-level propensity score analysis [9–11]
between the datasets of the CoCr-BP-BES in the Alpha
registry and the SS-BP-BES arm of LEADERS. .e pro-
pensity for each patient was modelled as the probability of
being part of the Alpha registry versus being part of the SS-
BP-BES arm in LEADERS. .e propensity scores were
obtained by inverse probability of treatment weight (IPTW).
.e full list of baseline variables used in the propensity score
calculation is provided in Supplementary Table S1.
While the Biomatrix Alpha Registry protocol was
designed to match the LEADERS protocol, post-PCI bio-
markers were encouraged in the Alpha Registry but man-
datory in the LEADERS study and the updated .ird
Universal Definition of myocardial infarction [6] was used
only in the Alpha Registry. Recognizing that different def-
initions might introduce a potential discrepancy in MI
reporting between the Alpha registry and the LEADERS
study, particularly for periprocedural MI (within 48 hours),
we then conducted a landmark analysis censoring clinical
events which were part of the primary endpoint occurring
up to day 3.
3. Results
3.1. Patient and Lesion Characteristics. Baseline patient and
lesion characteristics of CoCr-BP-BES versus SS-BP-BES are
shown in Table 1..emean age in the two groups was CoCr-
BP-BES 64.7± 11 years versus SS-BP-BES 64.6± 10.8 years
and 21% versus 24%, respectively, were current smokers..e
proportion of diabetes patients differed between the two
groups (CoCr-BP-BES 19.3% vs. SS-BP-BES 26.1%). Over
half of the patients in both groups presented with an acute
coronary syndrome (acute MI or unstable angina). Renal
insufficiency was more common in the CoCr-BP_BES group
(11.5% vs. 5.4%) but prior revascularization was more
common in the LEADERS study (24.6% vs. 40.9%). Pro-
cedural details are listed in Table 1. Use of DAPT in the
Alpha registry versus LEADERS study was lower at all time
points (96% vs. 98%; P< 0.001 at 30 days, dropping to 69%
vs. 93%; P< 0.0001 at 9months and 0% vs. 21%; P< 0.0001
at 2 years) reflecting evolving treatment guidelines, different
proportions of ACS patients, and greater use of single
antiplatelet therapy plus oral anticoagulation.
3.2. Clinical Outcomes. Previously published 9-month
MACE outcomes met criteria for noninferiority [3]. .e
unadjusted difference in MACE remained consistent at 2
years (6.6% with CoCr-BP-BES vs. 13.2% with SS-BP-BES;
HR 0.48[0.31–0.73]; P � 0.0005) (Figure 1). Individual
components of the composite MACE endpoint and unad-
justed secondary endpoints are listed in Table 2. Each
component of MACE and most secondary endpoints were
significantly lower in the CoCr-BP-SES group. A Cox re-
gression multivariate analysis, including 15 baseline char-
acteristics (Table S1) and stent type, found the stent type to
be an independent predictor of MACE (P � 0.0028).
3.3. Propensity Analysis. Given differences in patient base-
line characteristics despite using matching inclusion criteria,
a propensity analysis was undertaken and adjusted for 15
variables. Figure 2 shows that the difference in MACE
remained after propensity adjustment (7.4% vs. 13.3%; HR
0.52 [0.35 : 0.79]; P � 0.0041). Similar to the unadjusted
data, the difference in MACE emerged early then remained
consistent up to 2 years. Supplementary Figure 1 shows the
incidence of MACE during the first month versus months
2–24.
3.4. Stent 0rombosis. .e safety endpoint of definite or
probable stent thrombosis was adjudicated using identical
ARC criteria in both studies. Figure 3 shows that after
propensity adjustment, the incidence of definite or probable
stent thrombosis was markedly lower at 2 years with CoCr-
BP-DES (1.1 vs. 3.2%; HR 0.32 [0.114 : 0.897]; P � 0.034)
with most of the difference being in early stent thrombosis.
Of note, the reduction of definite or probable stent
thrombosis with CoCr-BP-DES was achieved despite a
shorter duration of DAPT.
3.5. Landmark Analysis at Day 3. To account for possible
differences in MI reporting, particularly for periprocedural
(Type 4a) MI, we conducted a landmark analysis censoring
clinical events contributing to the primary endpoint that
occurred up to and including day 3. Following landmark
analysis, the MACE rate with CoCr-BP-DES remained
numerically lower than with SS-BP-BES (Figure 4) but was
no longer statistically significant (7.25% vs. 9.34%; HR 0.76
[0.5–1.17]; P � 0.25). Individual elements of the composite
MACE endpoint and adjusted secondary endpoints fol-
lowing landmark analysis at day 3 are shown in Table 3. .e
patient-oriented composite endpoint remained significantly
lower with CoCr-BP-BES (11.7% vs. 18.7%; HR 0.6
[0.43–0.83]; P � 0.006) and there was a trend to less frequent
target vessel revascularization (5.8% vs. 9.1%; HR 0.63
[0.4–1.00]; P � 0.078).
4. Discussion
In this first report of longer-term (2-year) outcomes of
patients undergoing PCI with CoCr-BP-BES and at a time
point when all patients had discontinued dual antiplatelet
therapy, the unadjusted event rates with CoCr-BP-BES
remained low. .ese results are in keeping with recent data
from studies using other 3rd generation DES. .e BIO-
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RESORT randomized trial of 3514 all-comer patients [12]
and reported 2-year TVF rates of 6.8% for the SynergyTM
biodegradable polymer everolimus-eluting stent, 6.6% for
the OrsiroTM CoCr-BP-SES, and 8.3% for the RESOLUTETM
permanent polymer zotarolimus-eluting stent (ZES)
(P � ns). In the BIONYX trial [13], 2-year TVF rates were
7.6% with the Resolute OnyxTM permanent polymer ZES
and 7.1% with OrsiroTM
While thinner stent struts are associated with factors
such as reduced wall shear stress [14] and less malapposition
[15], both of which may reduce thrombotic risk, thinner
struts are more prone to longitudinal compression [16] and
to an increased risk of tissue prolapse increasing the
thrombotic risk [17]..inner struts may also impact on strut
spacing and impact local drug diffusion. It is thus important
to study DES strut thickness directly rather than extrapolate
from BMS data.
Previous DES studies have compared dissimilar tech-
nologies with differences in stent design, polymer, and drug
[2] which may confound analysis. While a meta-analysis of
thinner strut CoCr versus thicker strut SS-DES showed a
reduction in MI at 30 days [18], in SORT OUT VII, the
OrsiroTM CoCr-BP-SES failed to show a significant reduc-
tion in target lesion failure at 3 years compared with the
NoboriTM SS-BP-BES despite a marked difference in strut
thickness (60–80 µm vs. 114–120 µm) [19]. While our
comparison was not randomized, the prespecified protocol
of the Biomatrix Alpha Registry facilitated the comparison of
thin (84–88 µm) versus thicker (114–120 µm) struts in the 3rd
generation stents while controlling for the stent design,
polymer, and drug.
Although MI definitions differed between the 2 studies,
definite or probable stent thrombosis was adjudicated using
identical criteria. It was thus appropriate to report its in-
cidence without landmark adjustment. .e reduction in
definite or probable stent thrombosis rates is notable and is
Table 1: Baseline demographics and procedural details.
CoCr-BP-BES n� 400 SS-BP-BES n� 857 P value
Baseline demographics
Mean age (years) 64.7± 11 64.6± 10.8 0.892
Female gender (%) 21.5 25 0.178
STEMI or NSTEMI (%) 41.1 32.7 0.004
Unstable angina (%) 14 22.2 <0.001
Prior MI (%) 18.8 32.2 <0.0001
Previous PCI or CABG (%) 24.6 40.9 <0.0001
Previous stroke (%) 6.3 4.7 0.292
Current smoker (%) 21 24.1 0.229
Hypertension (%) 57.3 73.6 <0.0001
Dyslipidemia (%) 56.7 65.4 0.003
Diabetes (%) 19.3 26.1 0.009
Renal insufficiency (%) 11.5 5.4 <0.0001
Procedural details
Staged procedure (%) 5.5 4.4 0.476
Target lesion coronary artery (%)
LAD 47.4 37.2 <0.0001
LCX 20.1 28 <0.001
LM 2.3 2.6 0.399
RCA 26.9 30.7 0.112
De novo lesions (%) 95.9 94 0.123
Bifurcation lesions (%) 25.8 22.4 0.132
Number of stents per lesion 1.34± 0.70 1.20± 0.48 <0.0001
Severe calcification (%) 16.2 13.1 0.09
Lesion length (mm) 21.7± 12.8 15.2± 11.7 <0.0001
Reference vessel diameter (mm) 3.0± 0.5 2.6± 0.61 <0.0001
CABG�coronary artery bypass grafting, CoCr-BP-BES� cobalt-chromium biodegradable polymer Biolimus A9-eluting stent, MI�myocardial infarction,
PCI� percutaneous coronary intervention, and SS-BP-BES� stainless steel biodegradable polymer Biolimus A9-eluting stent.
Biomatrix Alpha vs LEADERS

































Figure 1: Unadjusted MACE at 2 years. CoCr-BP-BES� cobalt-
chromium biodegradable polymer Biolimus A9-eluting stent,
MACE�major cardiac adverse events, and SS-BP-BES� stainless
steel biodegradable polymer Biolimus A9-eluting stent.
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consistent with previous literature [2] suggesting that this
may be the principal benefit of reduced strut thickness.
.e strong trend towards lower cd-TVR with Biomatrix
Alpha shows that the antiproliferative effect of Biolimus was
not compromised despite the thinner strut platform.
.e limitations of this study are the modest sample size
and the use of historical rather than prospectively ran-
domized controls. It is possible that some of the outcome
benefits described are related to advances in procedural
techniques and concomitant drug therapy over the past
Table 2: Biomatrix Alpha versus LEADERS : unadjusted MACE at 2 years.
CoCr-BP-BES (n� 400) SS-BP-BES (n� 857) Hazard ratio P value
MACE 26 (6.65%) 112 (13.23%) 0.48 [0.31–0.73] 0.0005
- Cardiac death 4 (1.01%) 27 (3.21%) 0.31 [0.11–0.89] 0.022
- MI 12 (3.13%) 55 (6.48%) 0.46 [0.24–0.85] 0.012
- cd-TVR 16 (4.09%) 65 (7.8%) 0.51 [0.3–0.89] 0.0152
All death 15 (3.82%) 40 (4.72%) 0.79 [0.44–1.44] 0.449
Target vessel MI 5 (1.29%) 27 (3.18%) 0.39 [0.15–1.03] 0.048
Definite or probable stent thrombosis 3 (0.81%) 26 (3.07%) 0.25 [0.08–0.82] 0.013
Any revasc 29 (7.46%) 143 (17.14%) 0.40 [0.27–0.60] <0.0001
TVF (cardiac death or TV-MI or cd-TVR) 20 (5.09%) 96 (11.36%) 0.43 [0.27–0.7] 0.0004
POCE (all death or any MI or any revasc) 43 (10.9%) 192 (22.58%) 0.44 [0.32–0.61] <0.0001
revasc� revascularization, cd-TVR� clinically driven target vessel revascularization, CoCr-BP-BES� cobalt-chromium biodegradable polymer Biolimus A9-
eluting stent, MACE�major adverse cardiac events, MI�myocardial infarction, POCE� patient-oriented composite endpoint, SS-BP-BES� stainless steel
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Figure 2: Propensity-adjusted MACE at 2 years. CoCr-BP-BES� cobalt-chromium biodegradable polymer Biolimus A9-eluting stent,
MACE�major cardiac adverse events, and SS-BP-BES� stainless steel biodegradable polymer Biolimus A9-eluting stent.
Biomatrix Alpha vs LEADERS
















































Figure 3: Propensity-adjusted definite or probable stent thrombosis at 2 years. Stent thrombosis was adjudicated using identical criteria in
both studies. CoCr-BP-BES� cobalt-chromium biodegradable polymer Biolimus A9-eluting stent, MACE�major cardiac adverse events,
and SS-BP-BES� stainless steel biodegradable polymer Biolimus A9-eluting stent.
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decade, not fully adjusted for in the propensity analysis. In
line with typical registry protocols, only 10% of the patients
in the Alpha registry were fully monitored, thus there is a
possibility of underreporting of clinical events, although
100% adjudication of MACE events was undertaken.
5. Conclusion
In this analysis, 2-year clinical outcomes with the thin strut
(84–88um) Biomatrix AlphaTM CoCr-BP-BES were excel-
lent with rates of MACE at 6.6%, TVF 5.1%, and definite/
probable stent thrombosis 0.8%. A prespecified propensity-
adjusted analysis showed improved clinical outcomes
compared with the thicker strut (114–120 µm) Biomatrix
FlexTM SS-BP-BES.
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Figure 4: Propensity-adjusted MACE at 2 years with a landmark at day 3. CoCr-BP-BES� cobalt-chromium biodegradable polymer
Biolimus A9-eluting stent, MACE�major cardiac adverse events, SS-BP-BES� stainless steel biodegradable polymer Biolimus A9-eluting
stent.
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